Related Experiment Video
Updated: Feb 28, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer
Shuchi Lv1, Shanchuan Huang1, Langming Li1
1Department of Breast Center, Dongguan Kanghua Hospital, Dongguan, China.
Objectives:
This study conducted a bibliometric analysis of TIM-3 research in cancer in the past 25 years and expounded on the mainstream countries, institutions, authors, journals, and publications in this field. It intuitively depicts the evolution trajectory and future direction of TIM-3 research in the past 25 years.
Materials And Methods:
The published literature on the role of TIM-3 in cancer research was retrieved from the WoSCC and PubMed databases. Various bibliometric tools (including VOSviewer and CiteSpace) were used to identify the historical features, the evolution of active topics, and emerging trends.
Results:
A total of 1466 articles were retrieved, with the main contributors including China, the United States, and Japan. The journal with the most published articles was Frontiers in Immunology. Anderson AC is the core author of this research field. The most common keyword is "TIM-3." Furthermore, 37 clinical trial articles in the PubMed database were included. The analysis indicated that the main contributing countries were the United States, China, and Japan, with the United States being the pioneer of TIM-3 clinical research in cancer. Among these authors, Leena Gandhi published the highest number of articles. Keyword analysis indicated that most researchers experimentally validated and analyzed the characteristics of immune cells and biomarkers within the tumor microenvironment to predict clinical responses and mechanisms of resistance in cancer immunotherapy.
Conclusion:
The findings of this bibliometric study help researchers discover important topics and future research objectives by offering insights into the existing state and trends of TIM-3 in cancer.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

